China Pharma Holdings, Inc. (CPHI)
NYSEAMERICAN: CPHI · Real-Time Price · USD
1.980
0.00 (0.00%)
May 2, 2025, 4:00 PM EDT - Market closed
China Pharma Holdings Revenue
In the year 2024, China Pharma Holdings had annual revenue of $4.53M, down -35.41%. China Pharma Holdings had revenue of $1.13M in the quarter ending December 31, 2024, a decrease of -47.25%.
Revenue (ttm)
$4.53M
Revenue Growth
-35.41%
P/S Ratio
0.74
Revenue / Employee
$20,218
Employees
224
Market Cap
6.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.53M | -2.48M | -35.41% |
| Dec 31, 2023 | 7.01M | -1.09M | -13.48% |
| Dec 31, 2022 | 8.10M | -1.54M | -15.95% |
| Dec 31, 2021 | 9.64M | -1.22M | -11.27% |
| Dec 31, 2020 | 10.87M | -57.49K | -0.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
CPHI News
- 4 weeks ago - China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split - PRNewsWire
- 4 months ago - China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville - PRNewsWire
- 5 months ago - China Pharma Announces the Entry of "At-The-Market" Equity Offering - PRNewsWire
- 9 months ago - China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 - PRNewsWire
- 1 year ago - China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split - PRNewsWire
- 1 year ago - China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device - PRNewsWire
- 1 year ago - China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs - PRNewsWire
- 2 years ago - China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask - PRNewsWire